M&A Deal Summary

Oxford Immunotec Global Acquires Boulder Diagnostics

On August 5, 2014, Oxford Immunotec Global acquired medical products company Boulder Diagnostics for 8M USD

Acquisition Highlights
  • This is Oxford Immunotec Global’s 1st transaction in the Medical Products sector.
  • This is Oxford Immunotec Global’s 2nd largest (disclosed) transaction.
  • This is Oxford Immunotec Global’s 1st transaction in the United States.
  • This is Oxford Immunotec Global’s 1st transaction in Colorado.

M&A Deal Summary
Date 2014-08-05
Target Boulder Diagnostics
Sector Medical Products
Buyer(s) Oxford Immunotec Global
Deal Type Add-on Acquisition
Deal Value 8M USD

Target

Boulder Diagnostics

Boulder, Colorado, United States
Boulder Diagnostics is a private diagnostics company based in Boulder, Colorado that is developing immunology-based assays for rheumatology and infectious diseases. The primary focus of Boulder Diagnostics is on three products: Spirofind an assay to assist in the diagnosis of Lyme disease in both early and late-presenting forms, GoutifindTM an assay to assist in the diagnosis of Gout, obviating diagnosis by joint puncture, and StratokineTM an assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Oxford Immunotec Global

Abingdon, United Kingdom
Category Company
Founded 2002
Sector Medical Products
Employees260
Revenue 74M USD (2019)
DESCRIPTION

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company’s first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company’s second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. Oxford Immunotec Global was founded in 2002 and is based in Abingdon, the United Kingdom.

DEAL STATS #
Overall 1 of 3
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 3
State (Colorado) 1 of 1
Country (United States) 1 of 3
Year (2014) 1 of 1
Size (of disclosed) 2 of 3
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-23 Imugen

Norwood, Massachusetts, United States

Imugen, Inc. is a clinical and research laboratory located in Norwood, Massachusetts with over 25 years’ experience in the development and performance of specialized assays for tick-borne infections. Imugen is certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP) and is licensed as a clinical laboratory in Massachusetts, New York, Pennsylvania, Rhode Island and Maryland.

Buy $22M
Mergr

Product

Company

Legal